Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Stifel GMP Presentation

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Dec 08, 2021 4:00pm

89 Views

Post# 34211949

RE:Stifel GMP Presentation

Buy back and PP. So, about 7 years ago GUD did a private huge placement at $10. Investors bought on the expectation of fast growth, good investemnts nand profits. Thus a return of 8% on the $10 PP the today share price would have to be atleast at $15. Move forward to today GUD is buying back at $5 those share sold to stiffed investors for $10. Would any of those investors who bought the PP trust GUD? Further the

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages